利伐沙班效果怎么样呢？

Rivaroxaban is a new oral anticoagulant drug for adult patients with non-valvular atrial fibrillation (except for atrial fibrillation caused by rheumatic heart valve disease and atrial fibrillation after heart valve replacement). So, how effective is rivaroxaban?

The therapeutic effect of rivaroxaban:

Rivaroxaban highly selectively and competitively inhibits free and bound factor Xa and prothrombin activity, prolonging activated partial thromboplastin time (PT) and prothrombin time (aPTT) in a dose-dependent manner.

The essential difference between rivaroxaban and fondaparinux sodium/heparin is that it does not require the participation of antithrombin III and can directly antagonize free and bound factor During hip or knee replacement surgery, blood clots may form due to poor backflow of blood from leg veins to the heart. Rivaroxaban can help prevent the formation and further development of blood clots.

New anticoagulants were first used to prevent thrombosis after orthopedic surgeries, including total hip and knee replacement surgeries, and studies have reported that their effectiveness and safety are not inferior to low-molecular-weight heparin. Nowadays, new anticoagulants are gradually being widely used in the treatment of lower extremity venous thrombosis and pulmonary embolism. The latest ESC guidelines for the diagnosis and treatment of acute pulmonary embolism in 2014 mentioned that new anticoagulants can be used as an emerging anticoagulant to replace traditional anticoagulant treatments, and will also be gradually promoted in high-risk cardiovascular diseases such as atrial fibrillation and acute coronary syndromes.

Rivaroxaban, has been approved for the prevention of venous thrombosis (VTE) in adult patients undergoing hip or knee replacement surgery; and for the treatment of deep vein thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

Rivaroxaban is also recommended in adults with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism.